Invention Grant
US08455445B2 Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
有权
抑制TH1细胞相关疾病中淋巴毒素-β受体信号传导的方法
- Patent Title: Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
- Patent Title (中): 抑制TH1细胞相关疾病中淋巴毒素-β受体信号传导的方法
-
Application No.: US13037092Application Date: 2011-02-28
-
Publication No.: US08455445B2Publication Date: 2013-06-04
- Inventor: Jeffrey L. Browning , Christopher D. Benjamin , Paula S. Hochman
- Applicant: Jeffrey L. Browning , Christopher D. Benjamin , Paula S. Hochman
- Applicant Address: US MA Cambridge
- Assignee: Biogen Idec MA Inc.
- Current Assignee: Biogen Idec MA Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Debra J. Milasincic, Esq.
- Main IPC: A61K38/16
- IPC: A61K38/16 ; A61P19/02 ; C07K19/00 ; C07K14/715
Abstract:
This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
Public/Granted literature
Information query
IPC分类:
